Correction: Pediatric Nephrology
10.1007/s00467-025-07046-z
The original Table 1 included incorrect information. Below is the original table for reference, followed by the corrected version:
Original Table 1:
Table 1.
Summary of ongoing and recently completed clinical trials for AS. This table provides an overview of interventional studies currently evaluating or recently completing evaluation of investigational therapies in AS, including mechanism of action, target population, and study status
| Study | Drug | Mechanism | Population | Status | Sponsor |
|---|---|---|---|---|---|
| EPPIK | Sparsentan | Dual ETA/AT1 receptor blocker |
Pediatric (1–18yrs) |
Completed (Phase 2) |
Travere Therapeutics |
| ALPESTRIA-1 | Vonafexor | FXR agonist |
Adolescents and adults |
Completed (Phase 2) |
Genfit |
| ELX-02 | ELX-02 | Read-through compound (COL4 mutations) |
Pediatric (6–30 yrs) |
Ongoing (Phase 2) |
Eloxx Pharmaceuticals |
| FIONA | Finerenone | Non-steroidal MRA |
Pediatric (2–18 yrs) |
Recruiting (Phase 3) |
Bayer |
| R3R01-201 | R3R01 | Mediates cholesterol efflux by ABCA1 induction | Adults |
Ongoing (Phase 2) |
Chinook Therapeutics |
| VAR200-0301 | 2HPβCD | Mediates cholesterol efflux | Adults |
Ongoing (Phase 2) |
ZyVersa |
| MSC Trial | hUC-MSC | Stem cell therapy (anti-inflammation) | Not specified |
Planned (Phase 2) |
Guangzhou Women& Children’s |
| Setanaxib Study | Setanaxib | NOX1/4 inhibitor (anti-fibrotic) | Adults |
Completed (Phase 2) |
Calliditas Therapeutics |
| AFFINITY Study | Atrasentan | Selective ETA receptor antagonist | Adults |
Exploratory (Phase 2) |
Chinook Therapeutics |
| CARDINAL | Bardoxolone methyl | Nrf2 activator | Adolescents and adults |
Completed, negative (Phase 3) |
Reata Pharmaceuticals |
| EAGLE | Bardoxolone methyl | Nrf2 activator (long-term safety) | Adults |
Terminated (Phase 3) |
Reata Pharmaceuticals |
| HERA | Lademirsen (anti-miR-21) | microRNA inhibitor | Adolescents and adults | Terminated for futility | Sanofi |
| DOUBLE PRO-TECT Alport | Dapagliflozin | SGLT2 inhibitor | Adolescents and young adults | Recruiting | AstraZeneca |
Corrected Table 1:
Table 1.
Summary of Ongoing and recently Completed Clinical Trials for AS This table provides an overview of interventional studies currently evaluating or recently completing evaluation of investigational therapies in AS, including mechanism of action, target population, and study status
| Study name | Drug | Mechanism | Population | Status | Sponsor |
|---|---|---|---|---|---|
| EPPIK | Sparsentan | Dual ETA/AT1 receptor blocker | Pediatrics & Adolescents |
Recruiting (Phase 2) |
Travere Therapeutics |
| ALPESTRIA-1 | Vonafexor | FXR agonist | Adolescents & Adults |
Active, not recruiting (Phase 2) |
ENYO Pharma |
| ELX-02 | ELX-02 | Read-through compound (COL4 mutations) | Pediatrics & Adults |
Ongoing (Phase 2) |
Eloxx Pharmaceuticals |
| FIONA | Finerenone | Non-steroidal MRA | Pediatrics & Adults |
Recruiting (Phase 3) |
Bayer |
| R3R01-201 | R3R01 | Mediates cholesterol efflux by ABCA1 induction | Adolescents & Adults |
Completed (Phase 2) |
River 3 Renal Corporation |
| VAR200-0301 | 2HPβCD | Mediates cholesterol efflux | Adults |
Ongoing (Phase 2) |
ZyVersa |
| hUC-MSC | hUC-MSC |
Stem cell therapy (anti-inflammation) |
Pediatrics |
Planned (Phase 2) |
Guangzhou Women& Children’s Medical Center |
| Setanaxib | Setanaxib |
NOX1/4 inhibitor (anti-fibrotic) |
Adolescents & Adults |
Completed (Phase 2) |
Calliditas Therapeutics |
| AFFINITY | Atrasentn | Selective ETA receptor antagonist | Adults |
Active, not recruiting (Phase 2) |
Novartis Pharmaceuticals |
| CARDINAL | Bardoxolone methyl | Nrf2 activator | Adolescents & Adults |
Completed, negative (Phase 3) |
Biogen |
| EAGLE | Bardoxolone methyl | Nrf2 activator (long-term safety) | Adolescents & Adults |
Terminated (Phase 3) |
Biogen |
| HERA | Lademirsen (anti-miR-21) | microRNA inhibitor | Adolescents & Adults | Terminated for futility | Sanofi |
| DOUBLE PRO-TECT Alport | Dapagliflozin | SGLT2 inhibitor | Adolescents & Young Adults | Recruiting (Phase 3) | German Research Foundation DFG |
The original article has been corrected.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Claudia Lo Re, Email: cxl1870@miami.edu.
Alessia Fornoni, Email: afornoni@med.miami.edu.